Investigating a new RNA treatment for heart issues in Duchenne muscular dystrophy
Targeting myocardial fibrosis with a novel noncoding RNA in Duchenne muscular dystrophy
This study is looking at a new treatment using a special type of RNA called TY4, which comes from tiny particles in the body, to help reduce heart scarring in people with Duchenne muscular dystrophy (DMD), and it’s taken by mouth along with a protein from breast milk to make it easier for patients to use.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11009962 on NIH RePORTER |
What this research studies
This research explores the effects of a novel noncoding RNA called TY4, which is derived from extracellular vesicles, on reducing myocardial fibrosis in patients with Duchenne muscular dystrophy (DMD). The study focuses on how TY4 can modify disease progression by targeting macrophages and inducing beneficial changes at the molecular level. The treatment is administered orally, combined with a protein found in breast milk, making it a potentially accessible option for patients. The research aims to establish a new class of RNA drugs that could provide significant therapeutic benefits.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy, particularly those experiencing cardiac issues.
Not a fit: Patients without Duchenne muscular dystrophy or those not experiencing cardiac complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that reduces heart complications in patients with Duchenne muscular dystrophy.
How similar studies have performed: While the approach of using noncoding RNAs is relatively novel, other RNA-based therapies have shown success in treating various conditions, indicating potential for this new class of treatment.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Rogers, Russell — Cedars-Sinai Medical Center
- Study coordinator: Rogers, Russell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.